Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options

Article English OPEN
Lamb, Ruth; Rohrer, Jonathan D.; Lees, Andrew J.; Morris, Huw R.;
(2016)
  • Publisher: Springer Nature
  • Journal: Current Treatment Options in Neurology,volume 18 (issn: 1092-8480, eissn: 1534-3138)
  • Related identifiers: pmc: PMC4985534, doi: 10.1007/s11940-016-0422-5, doi: 10.13039/501100000765
  • Subject: Treatment | Movement Disorders (A Videnovich, Section Editor) | Corticobasal degeneration | Atypical Parkinsonism | Corticobasal syndrome | Richardson’s syndrome | Neurodegenerative diseases | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, Atypical Parkinsonism, Progressive supranuclear palsy, Steele-Richardson-Olszewski syndrome, Richardson's syndrome, Corticobasal degeneration, Corticobasal syndrome, Movement disorders, Neurodegenerative diseases, Parkinson-plus syndromes, Treatment, Tauopathies, Tau protein, FRONTOTEMPORAL DEMENTIA, PARKINSONS-DISEASE, CONTROLLED-TRIAL, BOTULINUM TOXIN, DOUBLE-BLIND, PHARMACOLOGICAL THERAPY, ALZHEIMERS-DISEASE, LEXICAL RETRIEVAL, SYMPTOMS, APHASIA | Steele-Richardson-Olszewski syndrome | Clinical Neurology | Tauopathies | Movement disorders | Parkinson-plus syndromes | Tau protein | Progressive supranuclear palsy

Opinion statement There are currently no disease-modifying treatments for progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or therapeutic treatments that are effective in controlling their symptoms. The use of most... View more
  • References (76)
    76 references, page 1 of 8

    1995;58D2]:167-73. Available from: http://www.

    pubmedcentral.nih.gov/articlerender.fcgi?artid= 1073312&tool=pmcentrez&rendertype=abstract.

    Neuropsychiatr Dis Treat. 2012;8:85-93.

    Morris HR, Wood NW, Lees AJ. Classic diseases revisited: progressive supranuclear palsy (Steele-RichardsonOlszewski disease). Postgrad Med J. 2008;1999:579-84.

    4. Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry. ENGLAND; 1985;48(12):1234-9.

    5. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. ENGLAND; 1997;62(4):352-6.

    6. Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. 1982;(1981):261-3.

    7. Tawana K, Ramsden DB. Progressive supranuclear palsy. Mol Pathol. 2001;54D6]:427-34. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1187134&tool=pmcentrez&rendertype=abstract.

    8. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. Elsevier Ltd; 2009;8(3):270-9. Available from: http://linkinghub.elsevier.com/ retrieve/pii/S1474442209700420.

    9. Mahapatra R, Edwards M, Schott J, Bhatia K. Review: corticobasal degeneration. Lancet Neurol. 2004;3(December):736-43.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark